Image Credit: Canva
We've all been there, you use the toilet, try to stand up, and suddenly your legs go numb. That odd pins-and-needles feeling can be surprising and uncomfortable. Though it might feel like a small inconvenience, it does have a scientific explanation. The numbness, also called transient paresthesia, happens when pressure blocks blood flow or presses on nerves in your lower extremities. It is normally harmless, but frequent occurrences can be signs of underlying health issues or poor toilet habits that must be addressed.
That weird numbness you experience after going to the bathroom is typically just a temporary annoyance, most often due to bad posture, straining, or sitting for an extended period. But if the numbness continues or gets worse, it is important to get medical guidance to make sure there are no underlying health issues. We discovered the top three reasons that could be responsible for this tingling and how can you avoid it? Let's dissect.
Struggling to push during a bowel movement can put excessive pressure on your abdomen and spine. This increased pressure can shift spinal discs, pressing against nerves that extend into your legs and feet. The result? A temporary loss of sensation, tingling, or weakness in your lower limbs.
Straining usually results from constipation, which in turn can be caused by a low-fiber diet, dehydration, or inactivity. If you notice that you're straining frequently, perhaps it's time to change your eating and drinking habits to help move your bowels more easily.
The way you sit on the toilet can also be a cause of that numbness in your legs. Most people are prone to hunching over when they are using their phones, reading, or just focusing too intensely. But this position can compress nerves and blood vessels in your pelvis, causing tingling or numbness.
When you sit slumped forward, you cut off blood supply to the lower half of your body, compressing nerves that travel from your pelvis to your toes. That's why the numbness will often radiate past your thighs and into your toes.
The more time you spend sitting on the toilet, the higher your chance of getting numb legs. Protracted sitting continually puts pressure on the nerves within your lower limbs, slowing blood flow and leaving you with the familiar pins-and-needles feeling.
If you habitually stay on the toilet for a long time, either from digestive problems or distractions such as browsing your phone, you may find that there is more numbness over the course of time. If constipation is leaving you on the toilet longer than normal, diet changes can calm your system.
Although periodic tingling is not a health issue, recurring numbness is a problem that needs to be addressed. Below are some professional-recommended ways of preventing it:
Being seated with your knees higher than your hips can make all the difference. Sitting this way enables your colon to unwind, facilitating smooth bowel movements while minimizing pressure on the lower parts of your body.
Don't slouch, as this squishes nerves and blood vessels, making numbness more likely. If necessary, lean your back against the toilet tank or wall to keep your posture good.
Specialists recommend five to ten minutes of toilet time per visit. If you are straining, stand up, walk around, and try later. Forcing the bowel movement can cause more damage than benefit, putting greater pressure on your spine and worsening numbness.
If constipation is a chronic problem, being hydrated and consuming fiber foods such as fruits, vegetables, and whole grains can get your digestive system back in working order.
Raising your feet using a toilet stool may position your body for a more natural and strain-free bowel movement. A squatting position keeps the rectal canal open, minimizing the need to push and reducing the risk of leg numbness.
Hard toilet seats can restrict circulation in your lower body, increasing the risk of numbness. A cushioned or padded toilet seat can provide better support, improving blood flow to the legs and feet while reducing pressure on the pelvis.
While it's normal to have some numbness in your legs from time to time when sitting on the toilet, ongoing tingling or numbness in your lower extremities may be a symptom of an underlying medical condition. If you find yourself experiencing:
It's best to see a healthcare expert to exclude conditions such as nerve compression, circulatory disorder, or spinal condition.
Credit: Canva
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, affects millions of people worldwide. The lifelong condition commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication, and, in some cases, surgery.
Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control, impacting their lives and costing healthcare systems millions.
Now, a team of UK researchers from the Universities of Oxford, Newcastle, and Cambridge has identified an important driver of inflammatory bowel disease (IBD).
The findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.
"Understanding what drives the inflammation provides a clear explanation for disease in this group of people and opens the door to new treatments that target the autoantibodies themselves or cells that produce those autoantibodies," said Professor Holm Uhlig, a pediatric gastroenterologist and director of the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford.
Also read: Alcohol Study Shelved By Trump Administration Published In Scientific Journal: What Did It Find?
The researchers analyzed more than 4,900 patients with IBD and discovered that:
Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body's key controls on inflammation, effectively remove the immune system's natural "brake" on inflammation, allowing inflammatory responses to continue unchecked.
The researchers found high levels of anti-IL-10 neutralizing autoantibodies in the blood of about 3.5% of IBD patients, including those with Crohn's disease and ulcerative colitis, but not in healthy individuals. This could equate to 15,000–20,000 people with IBD in the UK carrying these autoantibodies.
Read More: US FDA Approves First New Sunscreen Ingredient Since the 1990s
The researchers also found that the presence of these antibodies was strongly linked to carriage of a particular genetic variant known as HLA-DRB1*01:03.
The link between HLA-DRB1*01:03 and a severe form of inflammatory bowel disease was first identified by Oxford researchers 30 years ago.
The new findings show that people carrying this variant are far more likely to develop antibodies that block IL-10, helping explain how the gene contributes to disease.
The researchers say the findings support the development of a blood test to identify this subgroup of patients, helping clinicians move quickly toward more appropriate treatment.
As per the Centers for Disease Control and Prevention (CDC), IBD refers to a group of lifelong diseases that affect your intestines. The main types of IBD are ulcerative colitis and Crohn's disease.
Ulcerative colitis affects the large intestine, while Crohn’s disease can inflame any part of the digestive tract. Both are lifelong conditions of unknown cause that trigger abdominal pain, diarrhea and other complications, with no known cure.
Credit: Canva
With modern lifestyle changes, delayed childbearing, and other factors, infertility among Indians as young as 25 has become a looming public health concern for the country. However, the issue does not stop at the present.
A recent study published by The Menopause Society in their journal Menopause found that infertility may lead to earlier menopause, raising questions about the long-term reproductive health implications of this demographic shift.
Menopause is the final stage of a woman’s reproductive lifecycle, when menstruation stops, and she can no longer get pregnant. When the ovaries stop producing estrogen and progesterone, and a woman misses her period for 12 consecutive months, she has officially reached menopause.
Although menopause is a regular part of ageing, women typically reach menopause between 45 and 55 years of age. If menopause occurs before age 45, it is considered early menopause. If it occurs before 40, it is termed premature menopause – rarer than early menopause but involves the same causes, symptoms, and health risks.
While previous studies have been conducted to find a link between infertility and both early and premature menopause, they have had mixed results and did not consider the effect of different types of infertility; this study focuses on women with a history of primary infertility, women who have never achieved pregnancy, and have difficulty conceiving.
For the study, researchers examined the reproductive lifecycle of nearly 700 women in the U.S. – 461 with primary infertility and 530 without infertility – who were otherwise demographically similar (age, education, smoking status, etc.). It found that the 461 women had a 25% higher likelihood of reaching natural menopause about 1.2 years earlier than the 530.
Researchers also noted that women with underlying endometriosis as a cause of their infertility reached menopause between 40 and 44 years, much sooner than the national average of the United States, i.e., 52 years.
Possible explanations include accelerated ovarian ageing, reduced ovarian reserve, or the effects of endometriosis on ovarian function. But no matter the causes, the implications for women’s long-term health are substantial.
All women are born with a finite, predetermined number of eggs, which are sensitive to age, environmental toxins, medications, hormonal imbalances, and lifestyle factors. When exposed to such risk factors, especially over a long period of time, the DNA inside the eggs is altered, causing permanent genetic damage and reducing the egg quality and quantity.
As a core part of the reproductive process, any damage to the eggs directly affects reproductive health and, in turn, long-term systemic health.
Infertility impacts more than the ability to conceive and go through a pregnancy; it is often a sign of underlying health conditions and potential chronic illnesses, acting as a biomarker of increased all-cause mortality. Experiencing infertility itself increases a woman’s risk of developing cardiovascular disease, metabolic disorders, gynecologic cancers, etc., but reaching menopause early on top of that puts them at further health risk, adding osteoporosis and cognitive decline to the mix, along with the emotional distress and mental health challenges.
Indian women already reach menopause earlier than women in Western countries, with the average woman experiencing menopause at 46.2 years of age. With fertility rates dropping across the country, this study highlights just how critical it is to increase fertility awareness. Early screenings and regular fertility testing can help detect risks early and enable timely intervention, not only to combat the ongoing crisis but to ensure that women live healthy, fulfilling lives without impending morbidity.
Credit: AI Generated Image
A new oral GLP-1 medication has delivered encouraging results in a Phase 2b clinical trial for people living with type 2 diabetes.
According to AstraZeneca, its experimental tablet, elecoglipron, significantly lowered blood sugar levels and helped participants lose an average of 10.5% of their body weight after 26 weeks of treatment.
The findings were presented at the 2026 American Diabetes Association Scientific Sessions in New Orleans and published in The Lancet on June 8.
Elecoglipron joins a growing wave of GLP-1 therapies being developed as pills, offering an alternative to injectable drugs such as Ozempic, Wegovy, Zepbound, and Mounjaro.
The first oral GLP-1 treatment, Rybelsus from Novo Nordisk, received FDA approval in 2019 for adults with type 2 diabetes. Since then, oral options have continued to expand. In December 2025, the FDA approved a tablet version of Wegovy for weight management, while Eli Lilly’s oral obesity treatment, Foundayo, gained approval in April.
Independent experts say AstraZeneca’s results highlight the growing potential of non-injectable GLP-1 therapies for both diabetes and obesity treatment.
“It’s encouraging to see another oral medication demonstrating the benefits of GLP-1 therapy without requiring injections,” said Dr. Pouya Shafipour, a family and obesity medicine specialist at Providence Saint John’s Health Center in California.
Dr. Marilyn Tan, an endocrinologist and professor of medicine at Stanford University, noted that the rapidly expanding GLP-1 market could soon welcome another oral treatment option if elecoglipron succeeds in Phase 3 trials and ultimately secures FDA approval.
GLP-1 is a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called post-nutrition hormones, and they help you absorb the energy you just consumed.
GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. GLP-1 pills imitate that hormone, thereby silencing the food chatter in the brain. Interestingly, for some people, this food chatter is really quiet, and for others it is an outburst. So with GLP-1, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.
However, it is important to note that losing weight includes not just fat but muscle as well. Losing too much muscle can lead to reduced strength and a shorter life span. Notably, records show that most people who start taking them stop them at 12 weeks; therefore, it is important for some but not for others.
The side effects of these pills include:
© 2024 Bennett, Coleman & Company Limited